Advertisement

Topics

Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

09:10 EDT 14 Jun 2019 | SCRIP

Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for...

      

Related Stories

 

Original Article: Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path

NEXT ARTICLE

More From BioPortfolio on "Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path"

Advertisement
Quick Search
Advertisement
Advertisement